Kairos Pharma
LOS ANGELES, CA · Health Care · 2 employees
Kairos Pharma is focused on developing cutting-edge therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.
Funding history
- Series seed — $3.5M — Jan 2025
- Series seed — $675K — Apr 2023
Recent signals
- May 18, 2026: SEC 8-K (8.01): On May 18, 2026, Kairos Pharma, Ltd. issued a new investor presentation as part of its participation in the 2026 LD Micro Invitational XVI taking place in Los Angeles, CA from May 18-19, 2026. The presentation, delivered by CEO John Yu, aimed to update attendees on the company's clinical programs and partnering activities. This communication is significant for investors and stakeholders as it outlines the company's strategic direction and recent developments.
- Jan 28, 2025: Raised $3.5M in Series seed
- Dec 03, 2024: Launched Kairos Pharma Ltd. announces the addition of City of Hope Cancer Center for ENV105 clinical trial aimed at treating castrate-resistant prostate cancer.
- Apr 27, 2023: Raised $675K in Series seed
See plans & pricing → Track Kairos Pharma’s funding, hiring, and signals — with verified contacts — on Fundz.